Financial Statements Consolidated Statement of Comprehensive Income for the year ended 31December 2016 2015 2014 Notes $m $m $m Product Sales 1 21,319 23,641 26,095 Externalisation Revenue 1 1,683 1,067 452 Total Revenue 23,002 24,708 26,547 Cost of sales 4,126 4,646 5,842 Gross profit 18,876 20,062 20,705 Distribution costs 326 339 324 Research and development expense 2 5,890 5,997 5,579 Selling, general and administrative costs 2 9,413 11,112 13,000 Other operating income and expense 2 1,655 1,500 335 Operating profit 4,902 4,114 2,137 Finance income 3 67 46 78 Finance expense 3 1,384 1,075 963 Share of after tax losses in associates and joint ventures 10 33 16 6 Profit before tax 3,552 3,069 1,246 Taxation 4 146 243 11 Profit for the period 3,406 2,826 1,235 Other comprehensive income: Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability 20 575 652 766 Tax on items that will not be reclassified to profit or loss 4 136 199 216 439 453 550 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 21 1,050 528 823 Foreign exchange arising on designating borrowings in net investment hedges 21 591 333 529 Fair value movements on cash flow hedges 115 Fair value movements on cash flow hedges transferred to profit and loss 195 Fair value movements on derivatives designated in net investment hedges 21 4 14 100 Amortisation of loss on cash flow hedge 1 11 Net available for sale gains losses taken to equity 139 32 245 Tax on items that may be reclassified subsequently to profit or loss 4 86 87 50 1,339 791 956 Other comprehensive income for the period, net of tax 1,778 338 1,506 Total comprehensive income for the period 1,628 2,488 271 Profit attributable to: Owners of the Parent 3,499 2,825 1,233 Non-controlling interests 24 93 12 Total comprehensive income attributable to: Owners of the Parent 1,722 2,488 266 Non-controlling interests 24 94 5 Basic earnings per $0.25 Ordinary Share 5 $2.77 $2.23 $0.98 Diluted earnings per $0.25 Ordinary Share 5 $2.76 $2.23 $0.98 Weighted average number of Ordinary Shares in issue millions 5 1,265 1,264 1,262 Diluted weighted average number of Ordinary Shares in issue millions 5 1,266 1,265 1,264 Dividends declared and paid in the period 23 3,540 3,537 3,532 All activities were in respect of continuing operations.
$m means millions of US dollars.
138 AstraZeneca Annual Report and Form 20-F Information 2016 Financial Statements Consolidated Statement of Financial Position at 31December 2015 2016 Restated 2014 Notes $m $m $m Assets Non-current assets Property, plant and equipment 7 6,848 6,413 6,010 Goodwill 8 11,658 11,800 11,550 Intangible assets 9 27,586 22,646 20,981 Investments in associates and joint ventures 10 99 85 59 Other investments 11 727 458 502 Derivative financial instruments 12 343 446 465 Other receivables 13 901 907 1,112 Deferred tax assets 4 1,102 1,294 1,219 49,264 44,049 41,898 Current assets Inventories 14 2,334 2,143 1,960 Trade and other receivables 15 4,573 6,622 7,232 Other investments 11 884 613 795 Derivative financial instruments 12 27 221 Income tax receivable 426 387 329 Cash and cash equivalents 16 5,018 6,240 6,360 13,262 16,007 16,697 Total assets 62,526 60,056 58,595 Liabilities Current liabilities Interest-bearing loans and borrowings 17 2,307 916 2,446 Trade and other payables 18 10,486 11,663 11,886 Derivative financial instruments 12 18 9 21 Provisions 19 1,065 798 623 Income tax payable 1,380 1,483 2,354 15,256 14,869 17,330 Non-current liabilities Interest-bearing loans and borrowings 17 14,501 14,137 8,397 Derivative financial instruments 12 117 1 Deferred tax liabilities 4 3,956 2,665 1,796 Retirement benefit obligations 20 2,186 1,974 2,951 Provisions 19 353 444 484 Other payables 18 9,488 7,457 7,991 30,601 26,678 21,619 Total liabilities 45,857 41,547 38,949 Net assets 16,669 18,509 19,646 Equity Capital and reserves attributable to equity holders of the Company Share capital 22 316 316 316 Share premium account 4,351 4,304 4,261 Capital redemption reserve 153 153 153 Merger reserve 448 448 448 Other reserves 21 1,446 1,435 1,420 Retained earnings 21 8,140 11,834 13,029 14,854 18,490 19,627 Non-controlling interests 24 1,815 19 19 Total equity 16,669 18,509 19,646 FRPSDUDWLYHV KDYH EHHQ UHVWDWHG WR UHIOHFW DQ DGMXVWPHQW WR WKH DFTXLVLWLRQ DFFRXQWLQJ IRU 6 3KDUPD VHH 1RWHb The Financial Statements from pages138 to 196 were approved by the Board on 2 February 2017 and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director AstraZeneca Annual Report and Form 20-F Information 2016 139 Financial Statements Consolidated Statement of Changes in Equity for the year ended 31December Share Capital Total NonShare premium redemption Merger Other Retained attributable controlling Total capital account reserve reserve reserves earnings to owners interests equity $m $m $m $m $m $m $m $m $m At 1 January 2014 315 3,983 153 433 1,380 16,960 23,224 29 23,253 Profit for the period 1,233 1,233 2 1,235 Other comprehensive income 1,499 1,499 7 1,506 1 Transfer to other reserves 40 40 Transactions with owners Dividends 3,532 3,532 3,532 Issue of Ordinary Shares 1 278 279 279 Share-based payments 93 93 93 Transfer from non-controlling interests to payables 5 5 True-up to Astra AB non-controlling interest buy out 15 15 15 Net movement 1 278 15 40 3,931 3,597 10 3,607 At 31December 2014 316 4,261 153 448 1,420 13,029 19,627 19 19,646 Profit for the period 2,825 2,825 1 2,826 Other comprehensive income 337 337 1 338 1 Transfer to other reserves 15 15 Transactions with owners Dividends 3,537 3,537 3,537 Issue of Ordinary Shares 43 43 43 Share-based payments 131 131 131 Net movement 43 15 1,195 1,137 1,137 At 31December 2015 316 4,304 153 448 1,435 11,834 18,490 19 18,509 Profit for the period 3,499 3,499 93 3,406 Other comprehensive income 1,777 1,777 1 1,778 1 Transfer to other reserves 11 11 Transactions with owners Dividends 3,540 3,540 3,540 Dividends paid by subsidiary to non-controlling interest 13 13 Acerta put option Note 24 1,825 1,825 1,825 Changes in non-controlling interest Note 25 1,903 1,903 Issue of Ordinary Shares 47 47 47 Share-based payments 40 40 40 Net movement 47 11 3,694 3,636 1,796 1,840 At 31December 2016 316 4,351 153 448 1,446 8,140 14,854 1,815 16,669 1 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.
140 AstraZeneca Annual Report and Form 20-F Information 2016 Financial Statements Consolidated Statement of Cash Flows for the year ended 31December 2016 2015 2014 Notes $m $m $m Cash flows from operating activities Profit before tax 3,552 3,069 1,246 Finance income and expense 3 1,317 1,029 885 Share of after tax losses of associates and joint ventures 10 33 16 6 Depreciation, amortisation and impairment 2,357 2,852 3,282 Decrease in trade and other receivables 1,610 152 311 Increase decrease in inventories 343 315 108 Decrease increase in trade and other payables and provisions 341 114 2,089 Gains on disposal of intangible assets 2 1,301 961 Fair value movements on contingent consideration arising from business combinations 18 1,158 432 512 Non-cash and other movements 492 350 353 Cash generated from operations 5,234 5,174 8,792 Interest paid 677 496 533 Tax paid 412 1,354 1,201 Net cash inflow from operating activities 4,145 3,324 7,058 Cash flows from investing activities Upfront payments on business combinations 25 2,564 2,446 3,804 Payment of contingent consideration from business combinations 18 293 579 657 Purchase of property, plant and equipment 1,446 1,328 1,012 Disposal of property, plant and equipment 82 47 158 Purchase of intangible assets 868 1,460 1,740 Disposal of intangible assets 1,427 1,130 Purchase of non-current asset investments 230 57 130 Disposal of non-current asset investments 3 93 59 Movement in short-term investments and fixed deposits 166 283 34 Payments to joint ventures 10 41 45 70 Interest received 140 123 140 Payments made by subsidiaries to non-controlling interests 13 10 Net cash outflow from investing activities 3,969 4,239 7,032 Net cash inflow outflow before financing activities 176 915 26 Cash flows from financing activities Proceeds from issue of share capital 47 43 279 Repayment of obligations under finance leases 16 42 36 Issue of loans 2,491 5,928 919 Repayment of loans 884 750 Dividends paid 3,561 3,486 3,521 Hedge contracts relating to dividend payments 18 51 14 Payments to acquire non-controlling interests 102 Movement in short-term borrowings 303 630 520 Net cash outflow inflow from financing activities 1,324 878 2,705 Net decrease in cash and cash equivalents in the period 1,148 37 2,679 Cash and cash equivalents at the beginning of the period 6,051 6,164 8,995 Exchange rate effects 21 76 152 Cash and cash equivalents at the end of the period 16 4,924 6,051 6,164 AstraZeneca Annual Report and Form 20-F Information 2016 141
